Ventana and MedImmune collaborate

|By:, SA News Editor

Roche's (RHHBY -0.2%) Ventana Medical Systems and AstraZeneca's (AZN) MedImmune will jointly develop a PD-L1 immunohistochemistry assay to screen patients for MedImmune's clinical trials for MEDI4736, an anti-PDL1 therapy for non-small cell lung cancer. Financial terms are not disclosed.